Astrana Health (ASTH) Q2 2026 earnings review
Scaling Top-Line, But Core Margins Squeeze
Astrana Health delivered a strong top-line Q2, with total revenue up 49% YoY to $972.5M and Adjusted EBITDA jumping 43% to $68.9M. The market will like the raised FY26 EBITDA guidance ($255-$280M) and the rapid deleveraging. However, beneath the impressive consolidated growth, the core Care Partners segment—which accounts for 96% of gross revenue—saw operating income decline 14% YoY despite a 48% revenue surge. The company is relying entirely on its high-margin Care Enablement (technology/MSO) segment to drive profit growth, offsetting worsening profitability in the actual delivery of care.
🐂 Bull Case
General and administrative expenses dropped from 7.7% of revenue in 25Q2 to just 5.6% in 26Q2. The proprietary AI-native operating system is structurally reducing administrative overhead, allowing revenue to scale much faster than fixed costs.
The high-margin Care Enablement (SaaS/MSO) segment more than doubled revenue to $85.6M (+109% YoY), while operating income surged over 500% to $16.4M, proving the company's tech stack has massive monetization potential.
🐻 Bear Case
Despite adding $301M in YoY revenue (+48%), the core Care Partners segment's operating income actually shrank by 14% to $42.9M. Rising cost of services is outpacing top-line gains, likely driven by higher medical cost trends from acquired populations.
The physical Care Delivery segment saw operating losses widen by 238% to nearly $3.0M. The physical footprint is increasingly a drag on the otherwise asset-light, tech-driven narrative.
⚖️ Verdict: ⚪
Neutral. The consolidated numbers and raised guidance screen incredibly well, but the fundamental unit economics of the core risk-bearing segment are deteriorating. Investors should monitor if tech-driven efficiencies can eventually reverse the margin compression in the actual care delivery network.
Key Themes
Segment Profitability Divergence
A major break in trend is visible in the segment mix. While Astrana is growing revenue across all three segments, the profitability profile is rapidly diverging. Care Partners (the risk-bearing medical groups) and Care Delivery (clinics) are seeing severe margin compression. Care Partners' operating income fell 14% YoY despite 48% revenue growth. All consolidated profit expansion is currently being carried by the Care Enablement (technology) segment. If Care Enablement growth slows, consolidated margins will immediately compress.
Aggressive Shift to Full-Risk Contracts
Management continues a deliberate, aggressive shift into full-risk arrangements, seeking total cost of care responsibility. Full-risk capitated revenue has accelerated from 53% in 2022, to 73% in 2023, and now sits at 81% as of Q2 2026. This allows Astrana to capture more premium per member, driving the massive top-line beats, though it requires precise medical cost management to retain the upside.
AI-Driven G&A Leverage
Astrana is proving its narrative that it operates a highly scalable tech platform rather than just a roll-up of medical clinics. G&A expenses came in at $54.2M, representing just 5.6% of revenue—a dramatic 210 basis point improvement from 7.7% in Q2 2025. Automated interactions and AI workflows are directly replacing administrative headcount requirements.
Lapping the Prospect Acquisition
Astrana closed the transformative Prospect Health acquisition on July 1, 2025. This means Q2 2026 is the final quarter of 'easy' YoY comparisons before the acquisition officially laps. While Q2 posted 49% YoY revenue growth, next quarter's guidance of ~$1.015B implies that YoY growth will abruptly decelerate to the mid-single digits. The market may misinterpret this mechanical deceleration as a fundamental slowdown.
Strong Free Cash Flow Conversion
Free cash flow for the first six months of 2026 reached $92.9M, tracking beautifully against the company's full-year guidance of $105M to $132.5M. The business is capital-light (only $7.9M in YTD CapEx), enabling rapid debt paydown following last year's large M&A activity.
Other KPIs
This represents a massive jump and is the root cause of the segment's 14% operating income decline. The cost of delivering care grew faster than the capitated revenue received, indicating either a spike in utilization, higher acuity patients (from Medicaid redeterminations), or structurally higher cost trends from the integrated Prospect populations.
Down slightly from $429.5M at the end of 2025, but the company generated robust operating cash. Cash was primarily deployed toward $103.9M in debt repayment during the first half of the year, underscoring management's commitment to deleveraging.
Guidance
Decelerating YoY. While this represents a modest sequential acceleration from Q2's $972.5M, it marks the exact quarter Astrana laps the massive Prospect acquisition. YoY growth will drop from the current ~50% range to roughly ~6% at the midpoint.
Accelerating sequentially from the $68.9M delivered in Q2. This implies the company expects to maintain its ~7.4% Adjusted EBITDA margin profile on the higher expected revenue base.
Upgraded. Management raised the full-year outlook, reflecting confidence in back-half execution and continued synergy capture. The $267.5M midpoint implies a ~30% YoY growth over FY25's $205.4M.
Key Questions
Care Partners Margin Compression
Care Partners operating income declined 14% YoY despite 48% revenue growth. How much of this cost of services increase is driven by structural issues in the legacy Prospect book versus localized spikes in utilization?
Care Enablement Sustainability
Care Enablement operating income grew by over 500% YoY to essentially subsidize the bottom line this quarter. What is driving this explosive margin expansion, and what is a normalized run-rate for this segment going forward?
Organic Growth Post-Lapping
As we enter Q3 and officially lap the Prospect acquisition, what is the embedded organic growth rate expectation for membership and revenue across the consolidated business?